These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8497341)

  • 21. Repeated aspiration of ovarian follicles and early corpus luteum cysts in an in-vitro fertilization programme reduces the risk of ovarian hyperstimulation syndrome in high responders.
    Amit A; Yaron Y; Yovel I; Peyser MR; David MP; Botchan A; Lessing JB
    Hum Reprod; 1993 Aug; 8(8):1184-6. PubMed ID: 8408514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.
    Chen CD; Wu MY; Yang JH; Chen SU; Ho HN; Yang YS
    Fertil Steril; 1997 Aug; 68(2):287-91. PubMed ID: 9240258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing severe ovarian hyperstimulation syndrome in an in vitro fertilization/embryo transfer program. Use of follicular aspiration after human chorionic gonadotropin administration.
    Vrtovec HM; Tomazevic T
    J Reprod Med; 1995 Jan; 40(1):37-40. PubMed ID: 7722973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
    Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
    J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome.
    Aboulghar MA; Mansour RT; Serour GI; Amin YM; Sattar MA; elAttar E
    Fertil Steril; 1996 Nov; 66(5):757-60. PubMed ID: 8893680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?
    Lee C; Tummon I; Martin J; Nisker J; Power S; Tekpetey F
    Hum Reprod; 1998 May; 13(5):1157-8. PubMed ID: 9647538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome.
    Mansour R; Aboulghar M; Serour G; Amin Y; Abou-Setta AM
    Hum Reprod; 2005 Nov; 20(11):3167-72. PubMed ID: 16006465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization.
    Buyalos RP; Lee CT
    Fertil Steril; 1996 Jan; 65(1):1-10. PubMed ID: 8557121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is coasting effective for preventing ovarian hyperstimulation syndrome in patients receiving a gonadotropin-releasing hormone antagonist during an in vitro fertilization cycle?
    Delvigne A; Carlier C; Rozenberg S
    Fertil Steril; 2001 Oct; 76(4):844-6. PubMed ID: 11591427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison between nafarelin and leuprolide acetate for in vitro fertilization: preliminary clinical study.
    Dantas ZN; Vicino M; Balmaceda JP; Asch RH; Stone SC
    Fertil Steril; 1994 Apr; 61(4):705-8. PubMed ID: 8150114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
    D'Angelo A; Amso NN; Hassan R
    Cochrane Database Syst Rev; 2017 May; 5(5):CD002811. PubMed ID: 28535578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
    Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
    Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of varying stages of endometriosis on the outcome of in vitro fertilization-embryo transfer.
    Pal L; Shifren JL; Isaacson KB; Chang Y; Leykin L; Toth TL
    J Assist Reprod Genet; 1998 Jan; 15(1):27-31. PubMed ID: 9493063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oocyte quality and IVF outcome after coasting to prevent ovarian hyperstimulation syndrome.
    Delvigne A; Kostyla K; Murillo D; Van Hoeck J; Rozenberg S
    Int J Fertil Womens Med; 2003; 48(1):25-31. PubMed ID: 12643517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound for identification of high-risk patients.
    Al-Shawaf T; Zosmer A; Hussain S; Tozer A; Panay N; Wilson C; Lower AM; Grudzinskas JG
    Hum Reprod; 2001 Jan; 16(1):24-30. PubMed ID: 11139531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of purified gonadotrophins for ovarian stimulation in IVF.
    Jones GS
    Clin Obstet Gynaecol; 1985 Dec; 12(4):775-84. PubMed ID: 3938687
    [No Abstract]   [Full Text] [Related]  

  • 40. Critical ovarian hyperstimulation syndrome in a coasted in-vitro fertilization patient.
    Tortoriello DV; McGovern PG; Colon JM; Loughlin J; Santoro N
    Hum Reprod; 1998 Nov; 13(11):3005-8. PubMed ID: 9853846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.